101 related articles for article (PubMed ID: 20063550)
1. Preliminary experience with bevacizumab in combination with standard chemotherapeutic regimens in the treatment of non-small cell lung cancer: a retrospective study.
Emmanouilides C; Philippou D; Sapountzi E; Diamandidou E
Hematol Oncol Stem Cell Ther; 2008; 1(3):183-8. PubMed ID: 20063550
[No Abstract] [Full Text] [Related]
2. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
3. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
Peng TR; Wu TW
Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
[No Abstract] [Full Text] [Related]
4. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
10. Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
Bertino E; Villalona-Calero MA; Ross P; Grever M; Otterson GA
Ann Thorac Surg; 2011 Feb; 91(2):640. PubMed ID: 21256341
[No Abstract] [Full Text] [Related]
11. [Bevacizumab in the first-line therapy of advanced NSCLC].
Hasenöhrl N
Wien Med Wochenschr; 2007; 157(21-22):576-8. PubMed ID: 18157597
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
13. Advances in chemotherapy of non-small cell lung cancer.
Molina JR; Adjei AA; Jett JR
Chest; 2006 Oct; 130(4):1211-9. PubMed ID: 17035458
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
16. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for non-small-cell lung cancer.
Garassino MC; Hollander L; Torri V
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
[No Abstract] [Full Text] [Related]
18. Salvage with erlotinib plus bevacizumab: not in NSCLC.
Sculier JP; Meert AP; Berghmans T
Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
[No Abstract] [Full Text] [Related]
19. Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.
Araujo AM
J Clin Oncol; 2010 Mar; 28(8):e131; author reply e132. PubMed ID: 20100954
[No Abstract] [Full Text] [Related]
20. [Consolidation therapy in advanced non-small cell lung cancer].
Duchnowska R
Pneumonol Alergol Pol; 2010; 78(6):439-44. PubMed ID: 21077036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
